anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a natural health food and a preparation method thereof. The natural health food uses vegetables as main raw material sources, and uses dahurian angelica root, tuckahoe, orange peel, chrysanthemum flower, hemp seed, lily and almond as raw materials. The raw materials are extracted to obtain an extract which is concentrated into a liquid extract. The liquid extract is evenly blended with the fine powder of raw material slag so as to be dried after granulation. Thus, the natural health food is formed. The present invention has the preparation method that the raw materials are extracted by water so as to obtain the extract; the extract is decompressed and concentrated into the liquid extract; the liquid extract is evenly blended with the fine powder of the raw materials so as to be granulated and dried. The food has the action of immunoregulation, memory improvement, fatigue resistance, etc. The preparation method has the advantages of accurate batch charging and simple manufacturing process.
PURPOSE OF REVIEW: Defining the optimal parathyroid hormone (PTH) target in chronic kidney disease (CKD) is challenging, especially for bone outcomes, due to the substantial variability in the skeleton's response to PTH. Although PTH hyporesponsiveness is as integral a component of CKD-mineral bone disorder as elevated PTH levels, clinical awareness of this condition is limited. In this review, we will discuss factors and mechanisms contributing to PTH hyporesponsiveness in CKD. This knowledge may provide clues towards a personalized approach to treating secondary hyperparathyroidism in CKD.
RECENT FINDINGS: Indicates a link between disturbed phosphate metabolism and impaired skeletal calcium sensing receptor signaling as an important mediator of PTH hyporesponsiveness in CKD. Further, cohort studies with diverse populations point towards differences in mineral metabolism control, rather than genetic or environmental factors, as drivers of the variability of PTH responsiveness.
IN SUMMARY: Skeletal PTH hyporesponsiveness in CKD has a multifactorial origin, shows important interindividual variability, and is challenging to estimate in clinical practice. The variability in skeletal responsiveness compromises PTH as a biomarker of bone turnover, especially when considering populations that are heterogeneous in ethnicity, demography, kidney function, primary kidney disease and mineral metabolism control, and in patients treated with bone targeting drugs.
OBJECTIVE: To explore if low-level laser 589nm may stabilise stored whole blood and red blood cell suspension in vitro.
METHODS: The interventional study was conducted from November 2021 to April 2022 at the Postgraduate Medical Physics Laboratory, Mustansiriyah University, Baghdad, Iraq, and comprised blood samples from healthy adults. The samples were obtained put in tubes containing anticoagulant citrate-phosphate dextrose-adenine. Each sample was divided into eight equal aliquots and stored for 21 days at 4ºC. Of the 8 aliquots, 4 were takebn as controls, while the other 4 were irradiated by 589nm laser beam with a radiation dose of 50J/cm² for 15min. Stability test measured by the percentage of haemolysis of an overnight stored red blood cell in saline solution was done on days 0, 7, 14 and 21 for non-irradiated and radiated aliquots. Data was analysed using SPSS 24.
RESULTS: Eight subjects (4 males and 4 females) were included, with mean age 21±3 years (range: 19-24 years). Whole blood samples showed a significant reduction in haemolysis by 40%, 20% and 42% compared to the control samples at days 0, 7 and 14, respectively (p<0.05). Red blood cell suspension showed a significant reduction in haemolysis by 9% compared to the control samples only at day 21 (p<0.05).
CONCLUSIONS: Low-level laser 589nm beam at 50J/cm² radiation dose was more effective on the stability of stored whole blood than the red blood cell suspension.
Health matenance has always been mankind's fist priority.in last decades many efforts have been taken by Pediatricians and Doctors in order to bring this into reality .Although these efforts have been able to reduce the amount of tension attributed to humanity' but they have not ever been able capable of eliminating the total issue.lnvastigators have been researching to discover a better alternative for rooting out in nature . Methicillin-resistant Staphylococcus aureus (MRSA) refers to a group of gram-positive bacteria that are genetically distinct from other strains of Staphylococcus aureus. MRSA is responsible for several difficult-to-treat infections in humans. MRSA is any strain of S. aureus that has developed, through horizontal gene transfer and natural selection, rnultiple drug resistance to beta-lactam antibiotics. .beta.-lactam antibiotics are a broad spectrum group which includes some penams ¨ penicillin derivatives such as methicillin and oxacillin, and cephems such as the cephalosporins.Strains unable to resist these antibiotics are classified as methicillin-susceptible S. aureus, or MSSA. MRSA is common in hospitals, prisons, and nursing homes, where people with open wounds, invasive devices such as catheters, and weakened immune systems are at greater risk of hospital-acquired infection. MRSA began as a hospital-acquired infection, but has become community-acquired as well as livestock-acquired. The terrns HA-MRSA (healthcare-associated or hospital-acquired MRSA), CA-MRSA (community-associated MRSA) and LA-MRSA (livestock-associated) reflect this. MRSA is the main couse of bubble, pimple, exanthema, furuncle,rash.diseas and Life-threatening deseas Pneumonia, Meningitis, Osteomyelitis . Endocarditis, Toxic shock syndrome , Septicemi a. Staphylococcal infections are transmitted through contact with ulcers or skin-skin. Staphvlococc us aureus causes food gastroenteritis and food poisoning by producing enterotoxin in food. Staph ylococcus aureus causes the rnastitis in the cow. Staphylococcus aureus is also one of the five comrnon causes of hospital infections, especially post-surgical ulcers. Each year. 500,000 people are infected with Staphylococcus aureus in US hospitals
OBJECTIVE: Various systemic inflammation response indexes (SIRI) have repeatedly been described as prognostic factors in ovarian cancer. They have not been validated in prospective trials and published results are sometimes contradictory. We aimed to explore their role in a cohort of patients diagnosed with stage III and IV ovarian cancer treated at our institution.
METHODS: We retrospectively examined the prognostic influence of the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the monocyte-to-lymphocyte ratio (MLR), the red cell distribution width (RDW), and the mean platelet volume (MPV).
RESULTS: A total of 77 patients were analyzed. NLR > 2.243 at diagnosis, NLR before primary surgery, MLR at diagnosis, PLR > 289.1 at diagnosis, and PLR at diagnosis were significant in univariate Cox regression for progression-free survival, but none of them retained their significance in the multivariate Cox regression analysis. For overall survival, NLR >  = 2.53 at diagnosis, MLR >  = 0.245 at diagnosis, and PLR >  = 198.3 at diagnosis resulted significant in univariate COX regression; only PLR >  = 198.3 at diagnosis retained its significance in the multivariate analysis.
CONCLUSION: In our cohort, PLR >  = 198.3 was an independent prognostic factor for worse OS. The definitive role of SIRI in ovarian cancer has not yet been established. If their value as prognostic factors could finally be established, they would become a simple and economical method to predict prognosis in patients with advanced ovarian cancer. Therefore, it is time to conduct prospective, multicenter studies with larger samples to definitively establish its role in ovarian cancer, if any.
Patients will receive a single shot popliteal block (standard of care) and then undergo their standardized procedure. Patients will then receive 20cc Exparel and 10cc of normal saline at the conclusion of the case.
The invention relates to a hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength and a preparation method and an application thereof, and belongs to the field of chemical medicine. The compound is represented as the following formula described in the description. The compound of hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength has inhibition effects in different degrees on human liver cancer cell Hep G2 in anticancer activity evaluation in vitro. The ratio of photoactivity to dark activity and the ratio of sono-activity to dark activity are much higher than that of hemoporphyrinmonomethyl ether as a positive contrast. The hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength has advantages of low toxicity, high efficiency, treatment wavelength moving towards long wave region and the like. The compound in the invention can be used as an excellent photosensitizer and an excellent sonosensitizer for photodynamic and sonodynamic therapy of tumors.
The invention belongs to the technical field of medicines and provides a preparation method of selaginellin N being more than 95% in content from a traditional Chinese medicine selaginella tamariscina. A structure of the compound is represented as the following formula (I). The selaginellin N is prepared with dried whole herb of Selaginella tamariscina(Beauv.) Spring or Selaginella pulvinata(Hook.et Grev.) Maxim. as an initial raw material, and is prepared through extraction by an organic solvent and/or water and separation through a separation process with combination of macroporous resin adsorption and Sephadex LH-20 adsorption. The preparation method is simple in operations, is good in repeatability, is high in yield and is suitable in industrial production. The selaginellin N is high in purity and the content of the selaginellin N is not less than 95% through detection by HPLC.
Most individuals with obesity become so before age 35. In the US population, adolescents have the highest ultra- processed food consumption (68% of total energy) and the lowest diet quality. Given that ultra-processed foods represent two-thirds of the energy consumed by adolescents and young adults, research is needed to understand the influence of food processing on eating behaviors, particularly in the late adolescence and early adulthood life stage. During this time, individuals have increasing independence in food choice and it represents a key developmental period for executive function, processes that affect life-long mental and physical health. Evidence from pre-clinical studies demonstrates rodents maintained on a "cafeteria diet" comprised of ultra- processed ingredients have greater energy intake, weight gain, and alterations in brain circuitry that regulates both energy intake and executive function than those exposed to a standard diet. However, the impact of ultra- processed foods on the brain circuits underlying reward processing, food intake regulation, food choice, and executive function in humans is unknown. Controlled diet interventions are needed to fill this void. The overall objective of this research is to establish proof-of-concept for altered reward processing measured by brain response to an ultra-processed milkshake, an increase in ad libitum energy intake in a buffet meal, and adverse effects on executive function in response to a diet high in ultra-processed foods (81% total energy) compared to a diet emphasizing un/minimally-processed foods in individuals aged 18-25 years. To address our objective, 32 individuals aged 18-25 years (late adolescence/early adulthood) (BMI\<30) will undergo two 14-day controlled feeding conditions in a randomly assigned order. Diets will match the caloric needs of the individual and be matched for potential confounding factors including macronutrients, fiber, and energy density. To assess changes in reward processing, brain response to an ultra-processed milkshake will be assessed via functional magnetic resonance imaging before and after each feeding period (4 measurements). Measurements immediately following each feeding period will include ad libitum energy intake and food selection at a breakfast buffet meal (containing both ultra-processed and minimally processed foods), eating in the absence of hunger post-meal, and executive function. Although consumption of ultra-processed foods may contribute to dysregulation of energy intake, mechanisms are uncertain and existing dietary guidelines do not address ultra- processed food intake due to a lack of human experimental research. The proposed research could address this gap and inform dietary guidelines for individuals at a critical developmental life stage - late adolescence to early adulthood.
It is estimated that approximately 75% to 80% of patients with AIDS experience anemia, which can be caused by AIDS or by the therapy patients receive for AIDS treatment (for example, zidovudine \[AZT\]). Anemia is a condition in which a patient has below normal levels of hemoglobin, the substance in red blood cells that carries oxygen to all parts of the body. People with severe anemia may experience fatigue and shortness of breath with activity. Therefore, this condition can have a negative influence on a person's quality of life. Epoetin alfa, used to treat anemia, is a genetically engineered form of a natural hormone, erythropoietin, that stimulates red blood cell production. This is a randomized, double-blind, placebo-controlled, parallel group study with an open-label follow-up period that is designed to evaluate the safety and effectiveness of epoetin alfa treatment in patients with AIDS who are being treated with AZT. The study consists of 3 periods: a screening period to determine if patients are eligible for the study, a double-blind treatment period, and an open-label treatment period. Eligible patients will be randomly assigned to one of two groups: epoetin alfa 150 units per kilogram or matching placebo. Patients will be treated with study medication (injected under the skin) 3 times a week for 12 weeks, or until their hematocrit reaches 38% to 40%. In the open-label period, all patients receive epoetin alfa injected under the skin for up to 6 months. Effectiveness will be determined by the change in hemoglobin and hematocrit (laboratory tests used to evaluate the severity of anemia), transfusion requirements, the patient's quality of life assessment, and the physician's global evaluation of the drug effect. Safety assessments include the incidence and severity of adverse events during the study, changes in clinical laboratory tests (hematology, biochemistry, and urinalysis), vital signs, electrocardiograms (ECGs), and physical examination findings. The study hypothesis is that AIDS patients who are receiving AZT and who are treated with epoetin alfa will have a lower incident of anemia compared with patients receiving placebo.

Double-blind: epoetin alfa, 150 units per kilogram \[U/kg\] of body weight, or placebo, injected under the patient's skin 3 times a week for 12 weeks or until the hematocrit level reaches 38% to 40%. Open-label: epoetin alfa, 200 U/kg, 3 times a week for up to 6 months (once weekly after hematocrit reaches 38% to 40%). Dose may be adjusted up to 1500 U/kg per week, as needed.
Obstetrical brachial plexus paralysis (OBPP) refers to complete or partial injury of the brachial plexus produced at the time of birth. OBPP involves most commonly the upper cervical roots (C5, C6) resulting in muscle imbalance between internal and external rotators of the shoulder . Although the majority of the patients (80-90%) recover spontaneously, some have a remaining imbalance causing severe functional impairment . In addition to diminished function, prolonged muscle contractures result in bony deformities in both the glenoid and proximal humerus. Internal rotation contractures due to external rotational weakness are the most common deformity in OBPP. Contracture release, tendon transfers, and rotational osteotomies are surgical methods used, depending on the level of deformity and the patient's age. To achieve functional external rotation of the arm, contracted structures should be released first. Currently, there is a lack of consensus on which procedures over the best outcome for mobility and function, and what are the precise indications for each type of surgery. There is also a large variation of practice between centers
The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), was conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject's arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will conclude with Mirror Therapy (MFT), where the patient will face a mirror covering the punctured side at a 45-degree angle for proper hand visualization, engaging in hand exercises and wrist movements while observing their reflection.
The movement and posture abnormalities that are characteristic of cerebral palsy are associated with underlying abnormalities of muscle tone, including dystonia, spasticity, and rigidity. The subtypes of cerebral palsy are defined according to the predominant muscle tone abnormality, its distribution and severity. There is widespread agreement that CP subtypes should be divided into the following groups. Spastic subtypes (hemiplegia: unilateral asymmetric spasticity; diplegia: bilateral symmetric spasticity, lower limbs more affected than upper limbs; quadriplegia: bilateral symmetric spasticity, upper and lower limbs affected equally), dystonic or athetotic type; and other miscellaneous types: hypotonic, mixed types, etc. These descriptive definitions are not useful when forming homogeneous cohorts of CP subtypes in rehabilitation research studies. Even when a preceding training session establishes precise criteria for each subtype based on these definitions and uses a "four limb" approach (defining the dominant muscle tone abnormality and its severity in each limb) the interobserver agreement in the classification of CP subtypes remains poor. This may be because there are no widely accepted definitions for the most common muscle tone abnormalities in cerebral palsy (spasticity, rigidity, dystonia) and examination methods vary widely. Recently, an interdisciplinary group of clinicians published a consensus document in which they set forth clear definitions for these disorders of muscle tone and recommendations on how to examine for them. Since the CP subtypes are defined according to the dominant muscle tone abnormality, we hypothesize that it may be possible to achieve acceptable interobserver agreement in the classification of the CP subtypes if these definitions and standard examination techniques are incorporated into the preceding training session with the other accepted elements. To test this hypothesis we will train clinicians from three different areas of expertise: child neurology, physiatry, physical therapy to classify subtypes of CP using accepted methods (establishing precise criteria for the subtypes and using a four limb approach) and will also train them to identify muscle tone abnormalities using the definitions and standard examination techniques in the consensus document. Following this training, we will ask the same clinicians to classify subtypes of cerebral palsy in a group of CP children. We will then measure interobserver agreement for the classification of CP using the kappa statistic. Achieving acceptable interobserver agreement in the classification of CP subtypes may facilitate the formation of homogeneous cohorts in research studies.
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with triple negative breast cancer who have failed in previous routine systemic treatment. The study will be conducted in 2 parts: dose escalation and cohort expansion. In the first part, nine patients are injected with different dosage of the humanized anti-PD-1 antibody (1mg/kg or 3mg/kg or 10mg/mg, three patients in one group ) once and observed carefully in the following 4 weeks. If no dose-limiting toxicity (DLT) occurs, then they are injected every 2 weeks until disease progresses or unacceptable toxicity occurs. This part is to confirm DLT, maximum tolerated dose (MTD) and recommended dose (RD). In the second part, 6-12 patients are enrolled in each dosage group and injected with the humanized anti-PD-1 antibody every 2 weeks until disease progresses or unacceptable toxicity occurs. This part is to further analyze safety and efficacy of the humanized anti-PD-1 antibody.
Use of a conventional custom-made mouthguard while playing water polo for two weeks. The conventional mouthguard is designed with the palatal margin at 6 mm from the cervical line.
Group 2: Dental treatment was carried out using tell-show-do technique without any visual/auditory distraction in the second visit. The third visit consisted cartoon movie as a visual/auditory distraction.
Healthy obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
Infant formula containing 92 µg/100 g powder, providing approximately 110 µg iodine/day (i.e. 100% of the current AI). Unrestricted consumption during 11 days.
If the participant is assigned to Group C, they would receive $1.75 for each day that they meet their diabetes self-management goal. This equates to up to $49 every 4 weeks ($1.75 x 28 days = $49), or up to $588 over a period of 48 weeks. They would also receive $2.75 for each week that they meet their clinical outcome goal. This equates to up to $11 every 4 weeks ($2.75 x 4 weeks), or up to $132 over a period of 48 weeks. In total, they could earn up to $60 ($49 + $11) every 4 weeks, or up to $720 over a period of 48 weeks.
Subjects whose LDL higher than 160 mg/dl with subclinical atherosclerosis. Simvastatin is used to decrease cholesterol level for 7 weeks.